Measuring performance: Alfa Romeo F1 Team Stake announces partnership with Diagnostix
Alfa Romeo F1 Team Stake will bring cutting-edge technologies to the pinnacle of motorsport, as the team announces a partnership with leading medtech company, Diagnostix.
Founded in 2019, Diagnostix is a primary medtech company based in Europe, specialized in providing high-end AI assistance diagnostic tools to hospitals and medical facilities all around the world. With a mission to employ technology to improve people’s lives, Diagnostix will bring its expertise to a brand-new field – a team competing in the 2023 Formula One World Championship. The partnership between Alfa Romeo F1 Team Stake and Diagnostix brings together two brands at the top of their fields and with a strong commitment to technology and constant innovation.
Through the collaboration with Alfa Romeo F1 Team Stake, Diagnostix will be expanding into biometric performance analysis, an expansion from the company’s diagnostics tools and an area of significant interest, with ramification extending into everyday life.
As part of the agreement, Diagnostix’s logo will be sported on the helmets of Alfa Romeo F1 Team Stake drivers, Valtteri Bottas and Zhou Guanyu, as well as on their overalls and on the team’s 2023 challenger, the C43.
Alessandro Alunni Bravi, Team Representative of Alfa Romeo F1 Team Stake: “We are pleased to give the warmest welcome onboard to Diagnostix, the newest partner joining the ever-growing Alfa Romeo F1 Team Stake family. Wearable devices and advanced diagnostics tools have undergone huge development over the last few years, and Diagnostix is at the forefront of this revolution. Their innovative approach continues to push the boundaries of this field, and we’re proud to be part of the journey to provide fundamental insight into the performance and health of our drivers.”
Giuliano Senese, CEO of Diagnostix: “We are delighted to join Alfa Romeo F1 Team Stake, an iconic Formula One team with such a long history of success. We are thrilled to launch our biometric performance analytics technology and look forward to seeing how motorsports and our medical solutions can interact together to bring innovation in our respective fields.”